The global Infusion Pumps Market is consolidated at the top, with the top five players accounting for nearly 75%-80% of the market share in 2015. However, there are numerous small players in the market operating at the regional level. Some of the major players in the infusion pumps market are Becton, Dickinson and Company (U.S.), Pfizer Inc. (U.S.), Baxter International Inc. (U.S.), B. Braun Melsungen AG (Germany), and Fresenius SE & Co. KGaA (Germany). Other major players in this market include Medtronic plc (Ireland), Smiths Group plc (U.K.), Terumo Corporation (Japan), Moog, Inc. (U.S.), F. Hoffmann-la Roche Ltd. (Switzerland), and Johnson & Johnson (U.S.).
Download PDF Brochure @ http://www.marketsandmarkets.com/pdfdownload.asp?id=90374506
In 2015, Becton, Dickinson (BD) and Company dominated the global infusion pumps market. The acquisition of CareFusion Corporation (U.S.) in March 2015 helped BD enter into the infusion pumps market. This acquisition added CareFusion’s flagship Alaris infusion pumps to BD’s portfolio. The company’s revenue growth in 2015 is also attributed to its wide geographic reach, product portfolio, and sales in emerging markets (Eastern Europe, the Middle East, Africa, Latin America, and Asia-Pacific). The company’s comprehensive product portfolio includes numerous infusion systems such as volumetric infusion pumps, syringe infusion pumps, and PCA infusion pumps, under its market-leading brand Alaris. The company also provides dedicated disposables for its infusion products. BD has a strong focus on product innovation; over the years, the company has launched various innovative and technologically advanced products in the market. For this purpose, the company invests a significant amount of its revenue on R&D activities. It invested USD 632 million, USD 550 million, and USD 494 million on R&D in 2015, 2014, and 2013, respectively.
Pfizer Inc. held the second largest position in the global infusion pumps market in 2015. Its strong presence in well-established markets, especially the U.S., along with its wide range of product offerings, has helped it to retain its position amongst the top five players in the market. For instance, in 2016, the company launched the LifeCare PCA 7.0 patient-controlled analgesia (PCA) infusion pump with EMR. The continuous upgradation of infusion products and FDA approvals for the company’s Symbiq infusion systems have enabled the company to maintain its market position. However, in 2013, some of the company’s products were recalled, which negatively impacted the company’s revenue and is expected to hamper its market share in the coming years.
The top players in the global infusion pumps market are continuously striving to increase their market share with product launches, product upgrades, and geographic expansions. Some players are also focusing on acquisitions, collaborations, and agreements with similar companies to increase their customer base and garner greater market shares in the coming years. During 2013 to 2016, companies adopted collaborations and agreements as their major growth strategy. This strategy accounted for 37.2% of the total developments adopted by players in the market from 2013 to 2016.